Toxicity Profile of Panobinostat as seen in the PANORAMA Trial

Andrzej Jakubowiak, MD, PhD
Published Online: August 22, 2014
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Clinical Pearls:
  • In the PANORAMA trial, there was a higher proportion of GI toxicities in the panobinistat arm compared to the placebo arm.
  • A higher rate of thrombocytopenia and other hematological toxicities were also seen in the panobinostat arm.
  • However, all of the toxicities were mostly manageable and did not impact the outcome of the trial.
  • More details are needed to get a better understanding of the toxicity profile of this combination in this setting.


Related Articles
Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the novel anti-CXCR4 ulocuplumab for the treatment of multiple myeloma.
One of the leading non-clinical attributes that affect how oncologists decide which therapeutic agent to prescribe over another is patient affordability.
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.
Anti-CD38 monoclonal antibodies continue to demonstrate promise and generate excitement that a new treatment paradigm could be on the horizon for patients with multiple myeloma.
JTT Articles
Dacomitinib Shows Responses in Subset of Head and Neck Cancer
Immune Checkpoint Inhibitors for Renal Cell Carcinoma
Graft Versus Host Disease for the General Oncologist
External Resources

AJMC
Cure
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.